BMG PHARMA S.r.l. announces the launch of its proprietary product Ialuxid® Gel in the People’s Republic of China by Luqa Pharmaceuticals.

March 10th 2015
BMG Pharma S.r.l. is today pleased to announce the launch of its proprietary product Ialuxid® Gel in the People’s Republic of China.

In its Chinese version, Ialuxid® Gel is a non-antibiotic antimicrobial gel that maintains a moist wound environment that is conducive to healing, especially suitable for post-surgical wounds. Following the approval of Ialuxid® Gel in China, Luqa Pharmaceuticals will start the roll out of the product across the entire territory through its nationwide coverage.

“Since the start of our cooperation for Ialuxid® Gel in China in May 2013, Luqa has worked hard to get the product to market in a record time” said Marco Mastrodonato, CEO of BMG Pharma S.r.l. “We are pleased to offer Ialuxid® Gel to new patients in China, who will receive the best care possible through our innovative delivery technology that provides fast relief to skin infections. This long-term partnership is a major milestone for BMG as it opens us the door to the most exciting healthcare market in the world.”

“The launch of Ialuxid® Gel in China represents a big milestone for our company” said Robert Braithwaite, CEO of Luqa Pharmaceuticals. “Ialuxid® Gel is a great addition to our portfolio of skin solutions that aim at improving the quality of life of our patients. We are thankful for BMG’s support and we hope that this long-term collaboration will allow us to bring other of their key products to market in our territories.”

About Ialuxid®
Ialuxid® Gel is a unique combination gel formulation which is registered in Europe to treat acne lesions, folliculitis, paronychia, Molluscum Contagiosum and impetigo. The key ingredients in this novel formulation – hyaluronic acid, glycine and hydrogen peroxide – it forms a protective film against external agents and prevents the bacterial infections due to the synergistic effects against a wide range of micro-organisms and to a protective and effective filmogenic barrier to the skin.

About Luqa Pharmaceuticals
Luqa Pharmaceuticals is a China-focused company. We acquire, develop and commercialize innovative healthcare products that bring added value to prescribers and other healthcare providers while enhancing quality of life for patients. Since its inception in 2010, Luqa has become a fast-growing revenue generating company with a broad product portfolio and pipeline. We aim to become a leader in specialty care segments in China.

For press releases and other company information, visit:
and contact : Mr. Hugo Peris

About BMG
BMG is a specialty pharmaceutical company with head office in Milan, Italy, leveraging its proprietary technology to develop products that address unmet needs of patients. The company is currently focused on cancer supportive care, dermatology gynecology, ENT and oral health. BMG Pharma. is dedicated to helping patients, pharmacists and physicians by providing valuable and innovative products to the market.

The Company’s key features are:

  • Full involvement in business and partnering
  • Presence in different therapeutic areas
  • Specific regulatory strategies for each product as Prescription and OTC Medical Devices in EC and US to allow rapid market introduction. BMG focuses on bringing products to market quickly with supportive clinical data.
  • IP protection for most of the products and technologies

For press releases and other company information, visit:
and contact : Mrs. Loredana Galli

BMG Pharma S.r.l.